Clinical Trial Update: A Cohort Study on ctDNA MRD in Neoadjuvant Therapy for Pancreatic Cancer

View source ↗

Summary

A cohort study evaluating circulating tumor DNA minimal residual disease (ctDNA MRD) in neoadjuvant therapy for pancreatic cancer, including borderline resectab…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Borderline Resectable Pancreatic Adenocarcinoma
• Resectable Pancreatic Adenocarcinoma

Snippet

Sponsor: Ruijin Hospital | Conditions: Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma | Status: RECRUITING